Insulet 미래 성장

Future 기준 확인 2/6

Insulet (는) 각각 연간 8.3% 및 13.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 6.4% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.6% 로 예상됩니다.

주요 정보

8.3%

수익 성장률

6.4%

EPS 성장률

Medical Equipment 수익 성장	12.1%
매출 성장률	13.4%
향후 자기자본 수익률	17.6%
애널리스트 커버리지	Good
마지막 업데이트	15 Apr 2025

최근 미래 성장 업데이트

Recent updates

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Nov 20

Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?

Nov 20

Returns At Insulet (NASDAQ:PODD) Are On The Way Up

Nov 08

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues

Oct 15

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Oct 03

Is Insulet (NASDAQ:PODD) A Risky Investment?

Sep 09

Insulet: Turning More Constructive, Valuations Still Stretched

Sep 05

Here's Why We Think Insulet (NASDAQ:PODD) Is Well Worth Watching

Aug 28

Omnipod 5'S Global Expansion And New Integrations Promise Growth Amid Market And Manufacturing Risks

Aug 22 Expansion into new international markets and integration with leading diabetes sensors position Insulet for increased global penetration and competitive advantage.

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Aug 16

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Jul 15

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Jun 11

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

May 26

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

May 12

Is Insulet (NASDAQ:PODD) A Risky Investment?

Apr 29

Insulet: Insulating Patients, Investors Still Have To Wait

Mar 28

Insulet: An Interesting, Yet Expensive, Story

Jan 10

수익 및 매출 성장 예측

NasdaqGS:PODD - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	3,314	468	555	689	14
12/31/2026	2,873	386	465	562	22
12/31/2025	2,449	314	307	475	23
12/31/2024	2,072	418	296	430	N/A
9/30/2024	1,984	421	218	328	N/A
6/30/2024	1,873	395	182	285	N/A
3/31/2024	1,781	234	137	233	N/A
12/31/2023	1,697	206	37	146	N/A
9/30/2023	1,557	120	-15	151	N/A
6/30/2023	1,465	63	-26	152	N/A
3/31/2023	1,368	1	-45	133	N/A
12/31/2022	1,305	5	-38	119	N/A
9/30/2022	1,243	17	-63	43	N/A
6/30/2022	1,178	35	-141	-40	N/A
3/31/2022	1,142	45	-152	-47	N/A
12/31/2021	1,099	17	-191	-68	N/A
9/30/2021	1,037	-29	-199	-26	N/A
6/30/2021	996	-30	-126	44	N/A
3/31/2021	959	9	-120	53	N/A
12/31/2020	904	7	-82	84	N/A
9/30/2020	868	29	-15	114	N/A
6/30/2020	826	18	-25	101	N/A
3/31/2020	777	5	-65	88	N/A
12/31/2019	738	12	-72	98	N/A
9/30/2019	694	17	-74	82	N/A
6/30/2019	653	17	-103	67	N/A
3/31/2019	600	14	-126	47	N/A
12/31/2018	564	3	-126	36	N/A
9/30/2018	529	-13	N/A	27	N/A
6/30/2018	500	-17	N/A	35	N/A
3/31/2018	486	-23	N/A	59	N/A
12/31/2017	464	-27	N/A	41	N/A
9/30/2017	437	-29	N/A	39	N/A
6/30/2017	410	-30	N/A	19	N/A
3/31/2017	387	-26	N/A	5	N/A
12/31/2016	367	-27	N/A	16	N/A
9/30/2016	347	-34	N/A	-23	N/A
6/30/2016	324	-49	N/A	-17	N/A
3/31/2016	297	-62	N/A	-20	N/A
12/31/2015	264	-62	N/A	-13	N/A
9/30/2015	253	-51	N/A	11	N/A
6/30/2015	256	-44	N/A	7	N/A
3/31/2015	268	-56	N/A	6	N/A
12/31/2014	231	-48	N/A	9	N/A
9/30/2014	285	-49	N/A	1	N/A
6/30/2014	271	-59	N/A	0	N/A

애널리스트 미래 성장 예측

수입 대 저축률: PODD 의 연간 예상 수익 증가율( 8.3% )이 saving rate( 2.8% 보다 높습니다. ).

수익 vs 시장: PODD 의 연간 수익( 8.3% ) US 시장( 13.5% 보다 느리게 성장할 것으로 예상됩니다. 13.5% 연간).

고성장 수익: PODD 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: PODD 의 수익(연간 13.4% ) US 시장( 8.3% 보다 빠르게 성장할 것으로 예상됩니다. 8.3% 연간).

고성장 수익: PODD 의 수익(연간 13.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: PODD 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 17.6 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/04/16 20:43
장 마감 주가	2025/04/16 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Insulet Corporation 58 애널리스트 중 23 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Anand Vankawala	Avondale Partners
Jeffrey Johnson	Baird
null null	Baird

Insulet 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 7.0% to US$313

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2025 and Full Year Ending December 31, 2025

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates increase by 18%

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Recent updates

Insulet Corporation Launches Omnipod 5 Automated Insulin Delivery System in Canada

Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet?

Insulet Corporation to Report Q1, 2025 Results on May 08, 2025

Insulet Corporation Announces Executive Changes

Insulet Corporation Announces Omnipod 5 Automated Insulin Delivery (Aid) System Now Available in Australia

Insulet Leans Bullish (Technical Analysis)

Calculating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Price target increased by 7.0% to US$313

Full year 2024 earnings: EPS exceeds analyst expectations

Insulet Corporation Provides Revenue Guidance for the First Quarter Ending March 31, 2025 and Full Year Ending December 31, 2025

Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital

Earnings Not Telling The Story For Insulet Corporation (NASDAQ:PODD)

Executive VP notifies of intention to sell stock

Now 21% overvalued after recent price rise

Insulet Launches Revolutionary Omnipod 5 in Five More Countries in Europe

What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?

Insulet Corporation to Report Q4, 2024 Results on Feb 20, 2025

Executive VP recently sold US$1.2m worth of stock

Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly

Executive VP notifies of intention to sell stock

Here's Why Insulet (NASDAQ:PODD) Has Caught The Eye Of Investors

Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines

Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Returns At Insulet (NASDAQ:PODD) Are On The Way Up

Omnipod 5 App for Iphone Now Fully Available in the United States

Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues

Is There Now An Opportunity In Insulet Corporation (NASDAQ:PODD)?

Insulet Corporation to Report Q3, 2024 Results on Nov 07, 2024

Independent Chairman recently sold US$1.1m worth of stock

Independent Chairman notifies of intention to sell stock

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet: Turning More Constructive, Valuations Still Stretched

Here's Why We Think Insulet (NASDAQ:PODD) Is Well Worth Watching

Insulet Corporation Announces Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes

Omnipod 5'S Global Expansion And New Integrations Promise Growth Amid Market And Manufacturing Risks

Additional Considerations Required While Assessing Insulet's (NASDAQ:PODD) Strong Earnings

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

A Look At The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)

Insulet Corporation to Report Q2, 2024 Results on Aug 08, 2024

Now 9.0% overvalued after recent price rise

Now 20% overvalued after recent price rise

Insulet Corporation Announces SECURE-T2d Pivotal Trial Results Demonstrate Omnipod 5 Improves Clinical Outcomes and Quality of Life in Type 2 Diabetes

Insulet Announces Full Commercial Launch of Omnipod 5 with Expanded Sensor Integrations in the United Kingdom and the Netherlands

Independent Chairman recently sold US$1.3m worth of stock

Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023

Independent Chairman notifies of intention to sell stock

We Like These Underlying Return On Capital Trends At Insulet (NASDAQ:PODD)

Investor sentiment improves as stock rises 16%

At US$166, Is It Time To Put Insulet Corporation (NASDAQ:PODD) On Your Watch List?

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Revises Earnings Guidance for the Year Ending December 31, 2024

Is Insulet (NASDAQ:PODD) A Risky Investment?

Insulet Corporation, Annual General Meeting, May 22, 2024

Insulet Corporation to Report Q1, 2024 Results on May 09, 2024

Insulet: Insulating Patients, Investors Still Have To Wait

Insulet Corporation Appoints Ana Maria Chadwick as Executive Vice President, and Treasurer, Effective April 22, 2024

Insulet Corporation Presents Positive Results from its First Randomized Controlled Trial (RCT) Showing Improved Glycemic and Patient-Reported Outcomes in Type 1 Diabetes with the Omnipod 5 Automated Insulin Delivery System (Omnipod 5)

Insulet Corporation to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17Th International Conference on Advanced Technologies & Treatments for Diabetes

Director & Advisor notifies of intention to sell stock

Consensus EPS estimates increase by 18%

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Insulet Corporation Provides Unaudited Revenue Guidance for the Quarter Ending March 31, 2024 and Full Year Ending December 31, 2024

Insulet Corporation Announces Board Changes

Insulet Corporation to Report Q4, 2023 Results on Feb 22, 2024

Insulet: An Interesting, Yet Expensive, Story

Director & Advisor recently sold US$2.5m worth of stock

Director & Advisor notifies of intention to sell stock